Closed
Save

Request for Information on Country of Origin and API Source for Generic Pharmaceuticals

Department of Defense (DoD)
TBD
est. $148K – $1.9M

This opportunity is closed

The response deadline has passed. Review the details for future reference or to track similar opportunities.

Quick Brief

The Department of Defense is seeking information from industry regarding the manufacturing origin and active pharmaceutical ingredient sourcing for generic pharmaceutical products through a Request for Information (RFI). The Defense Logistics Agency (DLA) aims to evaluate supply chain transparency and potential country-of-origin disclosure requirements, requesting detailed information on manufacturing locations and the impact of proposed updated labeling requirements. This RFI is intended for market research and planning only and does not constitute a solicitation.

Generated 30d ago

Attachments

No files on SAM.gov

This listing does not include downloadable attachments. The solicitation details may be in the description below.

Verify on SAM.gov

Contract Details

Contract Type
TBD
Estimated Value
est. $148K – $1.9M

Agency & Contact

Contracting Organization

Agency
DEPT OF DEFENSE

Point of Contact

John A. Smith
Contracting Officer
(202) 555-0100

Key Dates

Published2mo ago
Mar 30, 2026
Last Updated2mo ago
Mar 30, 2026
Became Award Notice2mo ago
Mar 30, 2026
Tracked
Response Due2mo ago
Apr 2, 2026
Response Date2mo ago
Apr 9, 202615:00

Description

Defense Logistics Agency (DLA) Request for Information (RFI): Country of Origin and API Source Disclosure for Generic Pharmaceutical Products 1. Purpose In response to proposed legislation, the Defense Logistics Agency (DLA) is issuing this Request for Information (RFI) to gather data from industry regarding the manufacturing origin and active pharmaceutical ingredient (API) sourcing for generic pharmaceutical products. This RFI is for market research and planning only and does not constitute a solicitation or a commitment by the Government. 2.

Background DLA is evaluating supply chain transparency and potential country‑of‑origin disclosure

requirements for generic pharmaceuticals. Proposed legislation (summarized below) request that generic medicine include specific additional labeling

requirements. As part of this effort, DLA seeks detailed information on manufacturing locations of finished dosage forms and the county of origin for each API used in the listed products. In addition, DLA also seeks general respondent feedback on the impact of proposed updated label

requirements. Proposed Legislation: Country of Origin Labeling

Requirements for Generic Medicine Purchases

Get matched to contracts like this daily

Free AI-powered contract matching for your business.